This review provides a disuion ofcancer risk assessment methodology pertinent to devoping a strategy for extremely low frequency electric and magnetic fields (EMF). Approaches taken for chemical agents or ionizing radiation in six key topic areas are briefly rewed, and then those areas are examined from the perspective of EMF, identifing issues to be addressed in devoping a risk assessment strategy. The following recommendations are ofered: 1) risk assessment should be viewed as an iterative process that informs an overall judgment as to health risk and consists of a complex of related activities incorporating both positive and negative data, tumor and nontumor end points, and human and nonhuman sources of information; 2) a hazard identificaton resulting in a conclusion ofweak or null effects, such as may be associated with EMF, will need to assign significant weight to animal cancer bioassays conducted under defined exposure conditions as well as to human epidemiologic studies; 3) a default factor to account for possible age differences in sensitivity to carcinogenesis should be included in an EMF risk assessment; 4) lack ofevidence ofdose response and the apparent lack ofDNA reactivity of EMF suggest that a safety (or uncertainty) factor or margin ofexposure type of risk characterization may be most appropriate; and 5) an EMF risk assessment should permit at least tentative condusions to be reached as to the limits of carcinogenic risk from exposure to EMF, and should also define an efficient research agenda aimed at darifying uncertaities appropriate to a more complete assessment.
Efforts at assessing all or portions of the existing database of information relevant to the possible carcinogenic potential of electric and magnetic fields (EMF) have generally concluded that there is a lack of consistent evidence of human cancer risk from environmental exposures (1) (2) (3) (4) . These analyses have relied primarily on the large existing database of epidemiologic studies. As these groups point out, because of difficulties in assessing exposures, potential bias and confounding, as well as the inconsistency of epidemiologic studies, much uncertainty remains. Recent animal studies point to the possibility that EMF, though most likely nongenotoxic (5) (6) (7) , may have some potential to enhance the development of neoplasia [reviewed by the National Research Council (NRC) (2) and McCann et al. (8) ]. These promotion studies are currently undergoing independent replication (9) . In (10) as well as internationally (11) (12) (13) , programs are now in place that have the goal of using these data to develop comprehensive health risk assessments for EMF. Risk assessment encompasses a wide array of techniques that should be helpful in organizing the complex database on EMF for maximal utilization in a comprehensive and, hopefully, definitive health risk assessment. However, there are aspects of both the emerging biological effects profile and the exposure characteristics of EMF that raise unique problems for risk assessment. To our knowledge, there has been no comprehensive discussion of risk assessment methodology as it might be applied in a broad context to health effects data on EMF.
There is no definitive general method available for risk assessment. Though efforts to achieve scientific consensus on general principles for cancer risk assessment have been common [e.g., (14) ] and risk assessment has been routinely used in conjunction with regulatory decision making for some years [see the historical review by Albert (15) ], methods have never been consistently applied among the various regulatory agencies in the United States (16) , nor have the same approaches been taken in different countries (17) (18) (19) (20) .
In the United States, the EPA has taken a lead role in developing and implementing cancer risk assessment procedures on a large scale. The agency formally adopted a risk assessment procedure in 1986 (21) , which has become the standard of comparison in the field. However, over the past 10 years, a body of knowledge has accumulated that has precipitated an intensive reexamination of such so-called standard procedures. This new knowledge primarily involves changing ideas about cancer mechanisms, particularly about what is rate-limiting in carcinogenesis that may be subject to influence from environmental exposures; increasing awareness of the ubiquity of chemical carcinogens in the natural as well as the man-made environment; and increasing understanding that a significant number of cancer-causing substances do not interact directly with DNA.
National debate on the place of risk assessment in regulatory decision making has led to a congressionally mandated Commission on Risk Assessment and Risk Management (22) , to reexamination of risk assessment procedures by a Committee of the NRC on Science and Judgment in Risk Assessment (23), and to the recent release of a proposed revision of cancer risk assessment guidelines by the EPA (24) . All of these efforts advocate less emphasis on standard default procedures, a substantive role in risk assessment for a much wider range of data sources than in the past, and less reliance on quantitative risk estimates using highly uncertain dose-response extrapolation procedures. These reports are benchmark efforts around which reformulations of government mandated approaches to risk assessment are likely to coalesce in the next few years.
It is our aim to contribute to these discussions, focusing on scientific issues relevant to assessing potential cancer risk from exposure to EMF. We discuss six key topic areas: 1) variability between different human populations or individuals; 2) extrapolation between animals and humans; 3) the choice of an appropriate dose metric; 4) dose-response assessment and risk characterization; 5) the use of nontumor response data in risk assessment; and 6) the uses of epidemiology in risk assessment. [Exposure assessment, an area critical to developing a risk assessment strategy for EMF, is not addressed in this review. For recent discussion of this topic, see Bracken et al, (25) .] In a concluding section we offer several general recommendations that may help to guide the selection of risk assessment strategies for EMF.
The Issue of Uncertainty and the Selection of Defaults
The subjective nature of risk assessment has increasingly come under scrutiny. While both the NRC Committee on Science and Judgment in Risk Assessment (23, 26) and the EPA, in their newly proposed guidelines (24) , stress the importance of conveying the sources and, where possible, the amount of uncertainty in each risk analysis, of greatest concern are errors that do not have a statistical basis and are due to a limited understanding of carcinogenic mechanisms and biological processes. Though some techniques for dealing with this type of uncertainty do exist (27) (28) (29) (30) (31) , they are inherently limited because, until greater understanding of carcinogenic mechanisms emerges, criteria used by these techniques to assign certainty and plausibility are themselves subject to uncertainty.
The traditional approach for dealing with uncertainty without a statistical basis is to use so-called defaults, as originally suggested in 1983 by the NRC (32) . The EPA has consistently relied heavily on the use of defaults, although other organizations use them either not at all or sparingly, relying more on general principles of analysis and expert consensus (17, 33, 34) . While the recent NRC Committee on Science and Judgment in Risk Assessment recognized the necessity of using defaults, they criticized earlier practices, suggesting that increased attention be given to more precisely identifying and providing scientific and policy justifications for each default and for criteria guiding departures from defaults (35, 36) .
Thus, an initial area of focus in developing a risk assessment strategy for EMF will be first to determine the degree to which the analysis will rely on the use of defaults and, second, to select and define default options considered necessary. We discuss below three general areas where the adoption of defaults for EMF may be needed.
Variability between Different Human Populations or Individuals
Interpopulation or interindividual variability includes differences such as increased sensitivity of children and the aged as compared to healthy adults, differences between men and women due to hormonal factors, and differences due to the apparently wide distribution of genetic polymorphisms in a variety of traits that affect sensitivity to carcinogenesis (37) (38) (39) (40) .
Interpopulation or interindividual differences in sensitivity to EMF are not well documented. For example, laboratory studies to determine whether some individuals are unusually sensitive to the presence of electromagnetic fields have produced conflicting results [reviewed by Knave (41) ]. However, interindividual variation in sensitivity to chemical agents is well documented (42, 43) , and there is no reason to believe that analogous differences do not exist for EMF. This inference is supported by several lines of suggestive evidence. First, epidemiologic studies reporting a positive association between EMF surrogates and leukemia suggest that there may be greater sensitivity among children [for review see NRC (2) and Kheifets and Kelsey (44) ]. Second, it has been suggested that EMF may act through a receptor-mediated mechanism [see Kavet (45) for review] and may under certain conditions stimulate cell proliferation. Because genetic polymorphisms in cellular processes such as the control of cell proliferation and affinity differences of receptors involved in receptor-mediated carcinogenesis of agents such as TCDD, estrogens, and peroxisome proliferators have been observed (46) , it is not unlikely that if a receptor-mediated mechanism is established for EMF, similar interindividual differences may exist. And, third, blood levels of melatonin vary greatly among different individuals (47) , and suggested effects of extremely low frequency (ELF) electric or magnetic fields on the production of melatonin in experimental animals are the basis for a hypothesis (48) , albeit uncertain (49) (50) (51) (52) (53) , that reduced melatonin levels resulting from exposure to EMF may promote cancer in exposed individuals.
Should it be determined that use of a default assumption for interindividual/interpopulation variability is warranted for EMF, there is precedent for its use in regulatory practice. In the past, the primary use of interindividual/interpopulation defaults has been in conjunction with the regulation of noncarcinogens, and the magnitude of default factors used offers some precedent to assist in the selection of a default factor for EMF. For many years, regulatory agencies using a margin of safety (MOS) approach to regulate noncarcinogens have routinely used a 10-fold uncertainty factor to account for intraspecies variation [reviewed by Johannsen (54) ]. There is some experimental support for the magnitude of this uncertainty factor from laboratory studies with inbred rodent strains (55) . However, differences in sensitivity to specific agents can vary over a much larger range (56) , thus emphasizing the importance of better understanding the magnitude of possible interindividual or interpopulation differences in sensitivity to EMF effects.
Recently, the NRC Committee on Science and Judgment in Risk Assessment (23) recommended that default assumptions to account for interindividual variation be included in cancer risk assessments. In its proposed guidelines (24) , the EPA recommended the inclusion of a default uncertainty factor of 10-fold to account for interindividual variation (21, 24) for general discussion].
Most animal cancer tests of EMF are being conducted at magnetic field exposure levels far below those that would correspond to an MTD (although at levels 100-10,000 times the exposure levels suggested as possibly carcinogenic by some epidemiologic studies) (3, 8 1 has been used to scale short-circuit currents produced by externally applied electric fields between species, using the criterion of equivalency in effective surface area (75) , where effective surface area takes into consideration the erectness of posture when scaling between species. The internal current density induced by a vertically polarized external electric field acting on the body surface of grounded humans is 3.7-4.7 times greater than the internal current density due to the same external field acting on a rat (74) . Again, with some analogy to the pharmacokinetic distribution of chemicals, anatomically detailed models of various species reveal great differences in induced currents in different parts of the body. For example, in humans and rats exposed to vertical 60-Hz, 10-kV/m electric fields, the axial current densities in the neck and ankle, respectively, are 550 and 2,000 nA/cm2, a 3.6-fold ratio (human), and 40 and 1,100 nA/cm2, a 27.5-fold ratio (rat) (74) . Thus, for externally applied electric fields, the species scaling factor will vary depending upon which body part is of interest.
Species scaling considerations also apply for currents induced by externally applied magnetic fields (74 ,ased onthe commiee's discussion in the body of the report, we have inferred thatthe "specific feature' referred to in the executive summary is changes in ODC actvity. ' This value was reported in the executive summary of the NRC report In the body of the report, the conditons under which the two studies discussed as providing credible evidence of effects on ODC activity were conducted were 0.1 mV/cm (15JC and -Hz, 10 pT (15. drhis value was reported in the execute summary of the NRC report In the body of the report, three stdies were lised as meetng independent reproducibility requirements; two of these, Walleczek and Budinger (154, in which astidcally significant effects were deected using a 3-Hz pulsed magnetc field wih peaklux densites atS.5 or 28 mT, and Yost and Uburdy({53 in which effects were detected using a 16-Hz, 42 .1 itT magnetc field with co-linear static magnetc field of 23. 4 gT, appear in Table A3 -2 inthe committee report "The executive summary did not include an exposure level;the value reported is from Lfscher at al. (91) .
fThe committee did not evaluate bone healing in humans.
#lhis value was reported in the executive summary of the NRC report the conditons under which the studies evaluated by the committee were conducted wore 0.1-15 mT, 1-101 mA/cm'. generate their own electric fields internally in biological systems through magnetic induction, according to Faraday's Law. These internal fields result in induced currents termed eddy currents. Induced currents are measured in milliamps per square centimeter (mAIcm2). Currents induced by most environmental exposures to magnetic fields are believed to be smaller than currents that are endogenously present in the body (82) .
It should be clear from the above discussion that the determination of magnetic flux density inside the body is straightforward because it is equal to the external flux density. However, the determination of electric field strength inside the body is complex since it represents the combined effect of external and surface electric fields as well as induction by magnetic fields.
A variety of dose metrics have been suggested for EMF, most commonly measures related to field strength such as time-weighted average field strength, time exposed to field strengths above a certain threshold level, time exposed to field strengths within certain intensity windows, or the rate of change of field intensity. Other measures such as the frequency and intensity of switching transients or measures that are restricted to certain frequency windows have also been discussed [e.g., see Morgan and Nair (83) (2, 92) . However, very different exposure parameters have been observed to produce these effects (see Table 1 footnotes).
Thus, based on the analysis of the NRC committee (2) Table 3 ) and has used a low-dose extrapolation approach for all carcinogens, regardless ofwhether there is evidence for genotoxicity or DNA reactivity (21) . In their newly proposed guidelines, the EPA has modified this position. They have proposed an approach in which evidence for "gene mutation due to DNA reactivity" is used as a means of determining whether risk characterization approaches involving a default linear dose-response extrapolation or a default MOE/MOS approach will be used (24) . If there is evidence supporting DNA reactivity, the EPA proposes to use the former approach. In the absence of such evidence, the latter safety factor approach is proposed, provided there is additional evidence supporting a nonlinear mode of action. In the Volume 106, Number 1 1, November 1998 * Environmental Health Perspectives (65, 115, 116) (164-166) Table 4 ).
Third, analysis of tumorigenesis dose-response curves from the large database of animal bioassays of chemical agents now available indicates that a significant portion of these curves are more consistent with a quadratic rather than a linear dose-response (103) , that some dose-response curves demonstrate saturation (104) , that others even demonstrate hormetic effects (30, 105, 106) , and further, that there is no association between DNA reactivity and dose-response curve linearity (103 (6) . There is also some suggestion in the published literature that EMF may be capable of affecting biological processes such as cancer promotion, induction of ODC, and cell proliferation (see Table 1 and The Choice of an Appropriate Dose Metric). It is not our intention to evaluate these data, which must be considered uncertain unless independently replicated, but to present them as an example that illustrates that there is some evidence, however tentative, for the ability of EMF to enhance cellular processes associated with carcinogenesis that are believed to involve nonlinear mechanisms.
Two additional factors also support the conclusion that a scientific basis for the use of low-dose extrapolation methods in a risk assessment of EMF effects does not exist at this time. First, there are no plausible theoretical hypotheses or experimental biological data suggesting relevant mechanisms of action that could provide a basis for extrapolation. A number of biophysical mechanisms have been proposed to explain the interaction of EMF with biological systems (2, 110, 111) . These include energy coupling mechanisms, such as induced current effects; direct force mechanisms, such as forces on moving ions; mechanisms involving direct force effects on ferromagnetic partides; resonant mechanisms, such as ion cyclotron or parametric resonance; free radical mechanisms; and spatial and temporal signal-averaging mechanisms. All of these theories suffer either from serious theoretical difficulties or a lack of experimental support in living systems at field levels that are likely to be relevant to human exposure (112) . It is therefore premature to discuss how any particular theory might suggest a dose-response extrapolation strategy for EMF.
And second, endogenous electric fields in tissues provide a background on top of which induced fields must act to produce effects in intact living organisms (113, 114 (69, 109, (117) (118) (119) . In the EPA proposed guidelines, nontumor response data is accommodated in several ways. First, the concept of hazard identification has been expanded to include all pertinent sources of response data in a more substantive way than in previous guidelines. Such data could include, for example, nontumor response data indicating species specificity or data suggesting a threshold mechanism of action that might preclude extrapolation from the observable range of tumor dose response. Second, the EPA has proposed the use of quantitative response effects preceding tumorigenesis to enhance the analysis of tumor dose response in both observed and extrapolated ranges. Such effects might include, for example, cell proliferation, enzyme induction, or receptor binding. And, third, the EPA has proposed the use of biologically based or case-specific extrapolation models that incorporate nontumor response data, provided their relevance to mechanism is supported by sufficient data.
There are as yet no standard methods of using nontumor response data in quantitative risk assessment. However, as illustrated in Table 5 , there are general approaches that may be adaptable to specific cases, depending on the quality and availability of appropriate data. These indude 1) measurement of nontumor response parameters for direct use in a mathematical model [reviewed by Thorsland et al. (120) The five general approaches discussed above, while by no means exhausting the ways in which nontumor response data may be useful in risk assessment, suggest some approaches that may be useful to consider in developing risk assessment strategies for EMF. As discussed previously, several proposed biological effects of EMF involve nontumor end points that could affect carcinogenic processes (see Table 1 ). These indude effects on serum melatonin concentrations, ODC activity, calcium movement, and cell proliferation. These nontumor end points could in principle be incorporated into a risk assessment strategy, provided experimental or theoretical support emerges to provide linkage to an overall mechanism of action of EMF. For example, if a reduction in serum melatonin concentration was considered to occur prior to, and to be a prerequisite for, promotional effects of magnetic fields as proposed by Stevens (122) , a minimally effective dose could be determined using methods such as that suggested by Gastel and Sutter (123) (Table 5) or the benchmark dose (BMD) approach recommended in the proposed EPA guidelines (24) . The same procedures could be applied using other nontumor response data provided a plausible mechanistic linkage could be constructed.
Other potential applications of nontumor response data for EMF are apparent by analogy with the examples in (124) (125) (126) . Thus, whereas uncertainties associated with nonhuman data usually center on interspecies conversion and issues such as extrapolation below the near-toxic doses used in animal studies, uncertainties attendant to the use of human epidemiologic data are often dominated by issues stemming from difficulties in adequately defining exposures and adjusting for potential bias or confounding factors.
In the EPA's recently proposed risk assessment guidelines (24) there are two primary changes in the treatment of human epidemiologic evidence: 1) there is greater openness to a variety of uses of nontumor response information in both the hazard assessment and the dose-response assessment phases of risk assessment; and 2) there is increased einphasis on the need to include all epidemiologic studies, both positive and negative, in an overall evaluation of the carcinogenic potential of any agent.
Examples of uses of epidemiologic data in risk assessment that are consistent with these policy changes are described in Table  6 and are discussed below. 1 The use of data on the rate of formation and size of hepatocellular foci in rats to estimate an initiation rate for DNT. It was assumed that preneoplastic lesions could be represented by y-glutamyltranspeptidase-positive foci produced in rats pretreated with subinitiation doses of diethyinitrosamine followed by DNT. The number of foci was considered to be related to both the initiating and the promoting potential of DNT, but size of the foci was considered to be related only to the promoting potential of DNT. The use of data on the shape of the doseresponse curve for DNA adducts produced by 2-AAF in mouse liver to justify modeling the effect of 2-AAF on the probability of initiation as linear Measurement of the maximal binding capacity of the EGF receptor in liver as a function of TCDD dose to demonstrate that the receptor binding response is hyperbolic at low doses. If binding to the EGF receptor is rate limiting in the neoplastic process induced by TCDD, this result would suggest that cancer risk at doses below the observable range would be higher than predicted by a linear extrapolation from observed tumor responses Abrasive silicate crystals resulting from high doses of sodium saccharin in male rats lead to regenerative hyperplasia followed by bladder tumors. Thus, the dose-response curve for precipitation of abrasive crystals may be a more useful end point for assessing cancer risk than extrapolation from tumor dose response. 
continued, next page positive evidence from epidemiologic studies is still important in hazard assessment, the well-known difficulties in definitively establishing causation through epidemiologic studies involving environmental exposures has been taken into account by softening the former absolute requirement for positive epidemiologic evidence in order to assign a potential carcinogenic agent to the highest weight of evidence category. On the other side, a similar expansion in data required to assign a potential carcinogen to the category suggesting noncarcinogenicity ("not likely") has occurred. While "extensive human experience that demonstrates lack of effect" (24) will still result in a "not likely" category assignment, appropriate negative evidence from animal studies will also suffice. 2. Application of a meta-analysis and combined analysis of raw data (124,125,12$.
The procedures usually grouped under this heading indude using results from multiple epidemiologic studies in quantitative procedures involving weighting individual studies according to quality criteria and assessing heterogeneity. Results may also include the calculation of a summary risk estimate and new confidence intervals either using summary statistics based on multiple individual studies or using a pooled analysis with raw data. Application of these techniques is not well developed, and some attempts to simply obtain overall risk estimates or confidence intervals by combining summary statistics and the use of subjective quality weighting schemes have been criticized [see, for example, the recent debate in the American Journal of Epidemiology (130) (131) (132) (133) . Despite difficulties, these techniques offer a systematic approach to identifying potential sources of inconsistency and variability among Volume 106, Number 1 1, November 1998 * Environmental Health Perspectives Comparison of the potency of induction of DNA (184) adducts in mouse and human lymphocytes to obtain a species sensitivity conversion factor., This general approach may be adapted to inform the development of interspecies scaling factors specific to particular agents using any molecular, biochemical, or cellular end points believed to be critical in pathways leading to neoplasia, as long as the end points are measurable in vivo or in vitro in both rodent and human tissues. studies (124, 131, 133) . Guidelines for conducting meta-analyses have recendy been presented by a working group co-sponsored by the EPA (129) . In Table 6 (137) and risks derived from human occupational studies were compared. In both of these studies, predictions of human risk based on results from the animal studies were significantly higher than risks observed in the epidemiologic studies. 4 Table 6 , the statistical power of nine retrospective mortality studies of vinyl chloride workers were compared as a possible explanation for conflicting study results (139) . 5 . The use of dose-response models to estimate risk from epidemiologic data (124, 140, 141) . Much less attention has been given to developing methods for quantitative risk assessment using epidemiologic data than has been given to models using animal bioassay data. There are, however, some examples in the published literature of the application to epidemiologic study results of both empirical and biologically based models developed for use with animal bioassay data; two examples are described in Table 6 .
6. Using a "time window" type of analysis to define latency intervals. Shore and colleagues (124, 125) have discussed the use of epidemiologic studies to refine the temporal projection of risk in several populations, such as cigarette smokers, asbestos workers, and populations exposed to radon, for which both exposure and disease information are available over an extended time period. The example in Table 6 Table 5 could be applied in humans. However, in addition to the data limitations discussed above, the application of some of the approaches in Table 5 194) what might appear to be inconsistent epidemiologic results. In determining which risk assessment techniques may be helpful in analyzing (195 198) existing epidemiologic results and aiding in the design of future studies, the nine factors (197) (2, (145) (146) (147) (148) (149) (150) . For example, the NRC report on possible health effects of residential exposure to electric and magnetic fields included an assessment of the association between residential magnetic fields and childhood leukemia using the techniques of meta-analysis and concluded that the results for wire-codes were more consistent than those for measured fields (2).
Washburn et al. (149) performed an analysis across 13 epidemiologic studies that examined associations between residential proximity to power lines and childhood leukemia, lymphoma, and nervous system tumors. Kheifets First, while epidemiologic studies appropriately play an important role in hazard identification aimed at establishing the presence of a potent effect, a hazard identification aimed at establishing the possibility of weak or null effects, such as may be associated with EMF at environmental exposures, may have to assign greater weight to results of animal studies and other in vivo and in vitro sources of information. Although animal cancer bioassays suffer from statistical limitations and issues of relevancy to humans must be considered in interpreting results of assays in nonhuman systems, the ability to conduct these studies under controlled laboratory conditions using a wide range of defined exposures makes them uniquely valuable.
Second, because of the possibility that children may be at greater risk than adults from exposure to EMF, we recommend that a default factor to account for possible age differences in sensitivity to carcinogenesis be induded in an EMF risk assessment.
Third, current evidence does not justify the use of any dose-response extrapolation procedure in conjunction with an EMF risk assessment. The inclusion of such a procedure will require new experimental evidence of a dose-response effect on tumorigenesis or a cancer-related biological process, or a viable mechanistic hypothesis.
Fourth, it is likely that a plausible argument may be constructed, based primarily on the apparent lack of DNA reactivity of EMF, to justify the use ofsimple measures ofpotency that do not involve extrapolation below the experimentally observable range (Table 2) and risk characterization metrics such as the MOE (Table 3) , as recommended by EPA for so-called nonlinear carcinogens.
Finally, the development of any risk assessment strategy for EMF should take into account the fact that the current climate of risk assessment is much less formulaic than in previous years. As we have emphasized in this review, there is a much greater openness on the part of agencies such as the EPA to accommodate new approaches and agent-specific methodology. The use of nontumor data is probably the most exciting recent development in risk assessment (Table 5) . Consistent with the limitations of the EMF health effects database, it will be important to explore ways that such data might be incorporated into risk assessment strategies. Risk assessment is now much more research driven and, importantly, also research-driving than in the past. Thus, an iterative risk assessment strategy should indude not only procedures aimed at summarizing existing information in a way that informs as to potential health risks but it should also indude information that defines data gaps and research needs appropriate to a more complete assessment.
